Macrophage migration inhibitory factor exerts pro-proliferative and anti-apoptotic effects via CD74 in murine hepatocellular carcinoma.
CD74
apoptosis
chemokine
hepatocellular carcinoma
proliferation
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
23
06
2021
received:
16
11
2020
accepted:
25
06
2021
pubmed:
13
7
2021
medline:
15
12
2021
entrez:
12
7
2021
Statut:
ppublish
Résumé
Macrophage migration inhibitory factor (MIF) is an inflammatory and chemokine-like protein expressed in different inflammatory diseases as well as solid tumours. CD74-as the cognate MIF receptor-was identified as an important target of MIF. We here analysed the role of MIF and CD74 in the progression of hepatocellular carcinoma (HCC) in vitro and in vivo. Multilocular HCC was induced using the diethylnitrosamine/carbon tetrachloride (DEN/CCl DEN/CCl We identified a pro-tumorigenic role of MIF during proliferation and therapy-induced apoptosis of HCC cells. These effects were mediated via the MIF cognate receptor CD74. Thus, inhibition of the MIF/CD74 axis could represent a promising target with regard to new pharmacological therapies aimed at HCC.
Sections du résumé
BACKGROUND AND PURPOSE
Macrophage migration inhibitory factor (MIF) is an inflammatory and chemokine-like protein expressed in different inflammatory diseases as well as solid tumours. CD74-as the cognate MIF receptor-was identified as an important target of MIF. We here analysed the role of MIF and CD74 in the progression of hepatocellular carcinoma (HCC) in vitro and in vivo.
EXPERIMENTAL APPROACH
Multilocular HCC was induced using the diethylnitrosamine/carbon tetrachloride (DEN/CCl
KEY RESULTS
DEN/CCl
CONCLUSION AND IMPLICATIONS
We identified a pro-tumorigenic role of MIF during proliferation and therapy-induced apoptosis of HCC cells. These effects were mediated via the MIF cognate receptor CD74. Thus, inhibition of the MIF/CD74 axis could represent a promising target with regard to new pharmacological therapies aimed at HCC.
Substances chimiques
Antigens, Differentiation, B-Lymphocyte
0
Histocompatibility Antigens Class II
0
Macrophage Migration-Inhibitory Factors
0
invariant chain
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4452-4467Informations de copyright
© 2021 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Alexander, S. P. H., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Buneman, O. P., Cidlowski, J. A., Christopoulos, A., Davenport, A. P., Fabbro, D., Spedding, M., Striessnig, J., Davies, J. A., … CGTP Collaborators. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Other protein targets. British Journal of Pharmacology, 176(Suppl 1), S1-S20.
Bernhagen, J., Krohn, R., Lue, H., Gregory, J. L., Zernecke, A., Koenen, R. R., Dewor, M., Georgiev, I., Schober, A., Leng, L., Kooistra, T., Fingerle-Rowson, G., Ghezzi, P., Kleemann, R., McColl, S. R., Bucala, R., Hickey, M. J., & Weber, C. (2007). MIF is a non-cognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nature Medicine, 13, 587-596. https://doi.org/10.1038/nm1567
Bernhagen, J., Mitchell, R. A., Calandra, T., Voelter, W., Cerami, A., & Bucala, R. (1994). Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry, 33, 14144-14155. https://doi.org/10.1021/bi00251a025
Berres, M. L., Koenen, R. R., Rueland, A., Zaldivar, M. M., Heinrichs, D., Sahin, H., Schmitz, P., Streetz, K. L., Berg, T., Gassler, N., Weiskirchen, R., Proudfoot, A., Weber, C., Trautwein, C., & Wasmuth, H. E. (2010). Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. The Journal of Clinical Investigation, 120, 4129-4140. https://doi.org/10.1172/JCI41732
Bloom, B. R., & Bennett, B. (1966). Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science, 153, 80-82. https://doi.org/10.1126/science.153.3731.80
Cheng, B., Wang, Q., Song, Y., Liu, Y., Liu, Y., Yang, S., Li, D., Zhang, Y., & Zhu, C. (2020). MIF inhibitor, ISO-1, attenuates human pancreatic cancer cell proliferation, migration and invasion in vitro, and suppresses xenograft tumour growth in vivo. Scientific Reports, 10, 6741. https://doi.org/10.1038/s41598-020-63778-y
Choudhary, S., Hegde, P., Pruitt, J. R., Sielecki, T. M., Choudhary, D., Scarpato, K., DeGraff, D. J., Pilbeam, C. C., & Taylor, J. A. III (2013). Macrophage migratory inhibitory factor promotes bladder cancer progression via increasing proliferation and angiogenesis. Carcinogenesis, 34, 2891-2899. https://doi.org/10.1093/carcin/bgt239
De, R., Sarkar, S., Mazumder, S., Debsharma, S., Siddiqui, A. A., Saha, S. J., Banerjee, C., Nag, S., Saha, D., Pramanik, S., & Bandyopadhyay, U. (2018). Macrophage migration inhibitory factor regulates mitochondrial dynamics and cell growth of human cancer cell lines through CD74-NF-kappaB signaling. The Journal of Biological Chemistry, 293, 19740-19760. https://doi.org/10.1074/jbc.RA118.003935
Djudjaj, S., Martin, I. V., Buhl, E. M., Nothofer, N. J., Leng, L., Piecychna, M., Floege, J., Bernhagen, J., Bucala, R., & Boor, P. (2017). Macrophage migration inhibitory factor limits renal inflammation and fibrosis by counteracting tubular cell cycle arrest. Journal of the American Society of Nephrology: JASN, 28, 3590-3604. https://doi.org/10.1681/ASN.2017020190
Dumitru, C. A., Gholaman, H., Trellakis, S., Bruderek, K., Dominas, N., Gu, X., Bankfalvi, A., Whiteside, T. L., Lang, S., & Brandau, S. (2011). Tumor-derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation. International Journal of Cancer, 129, 859-869. https://doi.org/10.1002/ijc.25991
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004). Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology, 127, S35-S50. https://doi.org/10.1053/j.gastro.2004.09.014
Fingerle-Rowson, G., Petrenko, O., Metz, C. N., Forsthuber, T. G., Mitchell, R., Huss, R., Moll, U., Muller, W., & Bucala, R. (2003). The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proceedings of the National Academy of Sciences of the United States of America, 100, 9354-9359. https://doi.org/10.1073/pnas.1533295100
Heinrichs, D., Berres, M. L., Coeuru, M., Knauel, M., Nellen, A., Fischer, P., Philippeit, C., Bucala, R., Trautwein, C., Wasmuth, H. E., & Bernhagen, J. (2014). Protective role of macrophage migration inhibitory factor in nonalcoholic steatohepatitis. The FASEB Journal, 28, 5136-5147. https://doi.org/10.1096/fj.14-256776
Heinrichs, D., Brandt, E. F., Fischer, P., Kohncke, J., Wirtz, T. H., Guldiken, N., Djudjaj, S., Boor, P., Kroy, D., Weiskirchen, R., Bucala, R., Wasmuth, H. E., Strnad, P., Trautwein, C., Bernhagen, J., & Berres, M.-L. (2021). Unexpected pro-fibrotic effect of MIF in non-alcoholic Steatohepatitis is linked to a shift in NKT cell populations. Cell, 10, 252. https://doi.org/10.3390/cells10020252
Heinrichs, D., Knauel, M., Offermanns, C., Berres, M. L., Nellen, A., Leng, L., Schmitz, P., Bucala, R., Trautwein, C., Weber, C., Bernhagen, J., & Wasmuth, H. E. (2011). Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74. Proceedings of the National Academy of Sciences of the United States of America, 108, 17444-17449. https://doi.org/10.1073/pnas.1107023108
Hira, E., Ono, T., Dhar, D. K., El-Assal, O. N., Hishikawa, Y., Yamanoi, A., & Nagasue, N. (2005). Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer, 103, 588-598. https://doi.org/10.1002/cncr.20818
Huang, X. H., Jian, W. H., Wu, Z. F., Zhao, J., Wang, H., Li, W., & Xia, J. T. (2014). Small interfering RNA (siRNA)-mediated knockdown of macrophage migration inhibitory factor (MIF) suppressed cyclin D1 expression and hepatocellular carcinoma cell proliferation. Oncotarget, 5, 5570-5580. https://doi.org/10.18632/oncotarget.2141
Ji, S. Q., Su, X. L., Cheng, W. L., Zhang, H. J., Zhao, Y. Q., & Han, Z. X. (2014). Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1alpha pathway. Urologic Oncology, 32, 153-161. https://doi.org/10.1016/j.urolonc.2012.09.013
Kindt, N., Journe, F., Laurent, G., & Saussez, S. (2016). Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets. Oncology Letters, 12, 2247-2253. https://doi.org/10.3892/ol.2016.4929
Klasen, C., Ziehm, T., Huber, M., Asare, Y., Kapurniotu, A., Shachar, I., Bernhagen, J., & el Bounkari, O. (2018). LPS-mediated cell surface expression of CD74 promotes the proliferation of B cells in response to MIF. Cellular Signalling, 46, 32-42. https://doi.org/10.1016/j.cellsig.2018.02.010
Leng, L., Metz, C. N., Fang, Y., Xu, J., Donnelly, S., Baugh, J., Delohery, T., Chen, Y., Mitchell, R. A., & Bucala, R. (2003). MIF signal transduction initiated by binding to CD74. The Journal of Experimental Medicine, 197, 1467-1476. https://doi.org/10.1084/jem.20030286
Lilley, E., Stanford, S. C., Kendall, D. E., Alexander, S. P., Cirino, G., Docherty, J. R., George, C. H., Insel, P. A., Izzo, A. A., Ji, Y., Panettieri, R. A., Sobey, C. G., Stefanska, B., Stephens, G., Teixeira, M., & Ahluwalia, A. (2020). ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020. British Journal of Pharmacology. https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.15178
Liu, M., Zhou, J., Liu, X., Feng, Y., Yang, W., Wu, F., Cheung, O. K. W., Sun, H., Zeng, X., Tang, W., Mok, M. T. S., Wong, J., Yeung, P. C., Lai, P. B. S., Chen, Z., Jin, H., Chen, J., Chan, S. L., Chan, A. W. H., … Cheng, A. S. L. (2020). Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. Gut, 69, 365-379. https://doi.org/10.1136/gutjnl-2018-317257
Lu, M., Xu, Y., He, G., Liu, Q., Zhu, J., & Zhang, C. (2018). The expression of CD74 and macrophage migration inhibitory factor protein is upregulated in hepatitis B virus-related hepatocellular carcinoma. Translational Cancer Research, 7, 1537-1547. https://doi.org/10.21037/tcr.2018.11.21
Lue, H., Thiele, M., Franz, J., Dahl, E., Speckgens, S., Leng, L., Fingerle-Rowson, G., Bucala, R., Lüscher, B., & Bernhagen, J. (2007). Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene, 26, 5046-5059. https://doi.org/10.1038/sj.onc.1210318
Marin, V., Poulsen, K., Odena, G., McMullen, M. R., Altamirano, J., Sancho-Bru, P., Tiribelli, C., Caballeria, J., Rosso, N., Bataller, R., & Nagy, L. E. (2017). Hepatocyte-derived macrophage migration inhibitory factor mediates alcohol-induced liver injury in mice and patients. Journal of Hepatology, 67, 1018-1025. https://doi.org/10.1016/j.jhep.2017.06.014
Maubach, G., Lim, M. C., Kumar, S., & Zhuo, L. (2007). Expression and upregulation of cathepsin S and other early molecules required for antigen presentation in activated hepatic stellate cells upon IFN-gamma treatment. Biochimica et Biophysica Acta, 1773, 219-231. https://doi.org/10.1016/j.bbamcr.2006.11.005
McGrath, J. C., Pawson, A. J., Sharman, J. L., & Alexander, S. P. (2015). BJP is linking its articles to the IUPHAR/BPS Guide to PHARMACOLOGY. British Journal of Pharmacology, 172, 2929-2932. https://doi.org/10.1111/bph.13112
Mun, S. H., Won, H. Y., Hernandez, P., Aguila, H. L., & Lee, S. K. (2013). Deletion of CD74, a putative MIF receptor, in mice enhances osteoclastogenesis and decreases bone mass. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 28, 948-959. https://doi.org/10.1002/jbmr.1787
Njei, B., Rotman, Y., Ditah, I., & Lim, J. K. (2015). Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology, 61, 191-199. https://doi.org/10.1002/hep.27388
Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., Emerson, M., Garner, P., Holgate, S. T., Howells, D. W., Karp, N. A., Lazic, S. E., Lidster, K., MacCallum, C. J., Macleod, M., … Würbel, H. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biology, 18(7), e3000410. https://doi.org/10.1371/journal.pbio.3000410
Reiberger, T., Chen, Y., Ramjiawan, R. R., Hato, T., Fan, C., Samuel, R., Roberge, S., Huang, P., Lauwers, G. Y., Zhu, A. X., Bardeesy, N., Jain, R. K., & Duda, D. G. (2015). An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. Nature Protocols, 10, 1264-1274. https://doi.org/10.1038/nprot.2015.080
Saviano, A., Roehlen, N., Virzi, A., Roca Suarez, A. A., Hoshida, Y., Lupberger, J., & Baumert, T. F. (2019). Stromal and Immune Drivers of Hepatocarcinogenesis. In Y. Hoshida (Ed.), Hepatocellular carcinoma: Translational precision medicine approaches (pp. 317-331). Cham (CH).
Schwabe, R. F., & Luedde, T. (2018). Apoptosis and necroptosis in the liver: A matter of life and death. Nature Reviews Gastroenterology & Hepatology, 15, 738-752. https://doi.org/10.1038/s41575-018-0065-y
Shi, X., Leng, L., Wang, T., Wang, W., Du, X., Li, J., McDonald, C., Chen, Z., Murphy, J. W., Lolis, E., Noble, P., Knudson, W., & Bucala, R. (2006). CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity, 25, 595-606. https://doi.org/10.1016/j.immuni.2006.08.020
Sia, D., Villanueva, A., Friedman, S. L., & Llovet, J. M. (2017). Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology, 152, 745-761. https://doi.org/10.1053/j.gastro.2016.11.048
Ssadh, H. A., Abdulmonem, W. A., Rasheed, Z., Madar, I. H., Alhoderi, J., Eldeen, S. K. N., Alradhwan, A., Alasmael, N., Alkhamiss, A., & Fernández, N. (2019). Knockdown of CD-74 in the proliferative and apoptotic activity of breast cancer cells. Open Access Macedonian Journal of Medical Sciences, 7, 3169-3176. https://doi.org/10.3889/oamjms.2019.354
Tanese, K., Hashimoto, Y., Berkova, Z., Wang, Y., Samaniego, F., Lee, J. E., Ekmekcioglu, S., & Grimm, E. A. (2015). Cell surface CD74-MIF interactions drive melanoma survival in response to interferon-gamma. The Journal of Investigative Dermatology, 135, 2775-2784. https://doi.org/10.1038/jid.2015.204
Uehara, T., Pogribny, I. P., & Rusyn, I. (2014). The DEN and CCl4 -induced mouse model of fibrosis and inflammation-associated hepatocellular carcinoma. Current Protocols in Pharmacology, 66. https://doi.org/10.1002/0471141755.ph1430s66
Varinelli, L., Caccia, D., Volpi, C. C., Caccia, C., De Bortoli, M., Taverna, E., Gualeni, A. V., Leoni, V., Gloghini, A., Manenti, G., & Bongarzone, I. (2015). 4-IPP, a selective MIF inhibitor, causes mitotic catastrophe in thyroid carcinomas. Endocrine-Related Cancer, 22, 759-775. https://doi.org/10.1530/ERC-15-0299
Verjans, E., Noetzel, E., Bektas, N., Schutz, A. K., Lue, H., Lennartz, B., Hartmann, A., Dahl, E., & Bernhagen, J. (2009). Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC Cancer, 9, 230. https://doi.org/10.1186/1471-2407-9-230
Wang, D., Luo, L., Chen, W., Chen, L. Z., Zeng, W. T., Li, W., & Huang, X.-H. (2014). Significance of the vascular endothelial growth factor and the macrophage migration inhibitory factor in the progression of hepatocellular carcinoma. Oncology Reports, 31, 1199-1204. https://doi.org/10.3892/or.2013.2946
Wang, D., Wang, R., Huang, A., Fang, Z., Wang, K., He, M., Xia, J. T., & Li, W. (2018). Upregulation of macrophage migration inhibitory factor promotes tumor metastasis and correlates with poor prognosis of pancreatic ductal adenocarcinoma. Oncology Reports, 40, 2628-2636. https://doi.org/10.3892/or.2018.6703
Wirtz, T. H., Loosen, S. H., Schulze-Hagen, M., Gorgulho, J., Kandler, J., Joerdens, M., Demir, M., Mohr, R., Bruners, P., Kuhl, C., Trautwein, C., Berres, M.-. L., Tacke, F., Luedde, T., & Roderburg, C. (2021). Macrophage migration inhibitory factor predicts an unfavorable outcome after TACE for hepatic malignancies. Clinical and Translational Science. https://doi.org/10.1111/cts.13033
Zhang, C., Liang, T., Song, J., Jiang, S., Qu, L., & Hou, G. (2011). Evaluation of macrophage migration inhibitory factor as an imaging marker for hepatocellular carcinoma in murine models. Scandinavian Journal of Gastroenterology, 46, 720-726. https://doi.org/10.3109/00365521.2011.568517